| Aug 2 |
Ultragenyx Pharmaceutical Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 1 |
Ultragenyx Pharmaceutical GAAP EPS of -$1.52 beats by $0.13, revenue of $147.02M beats by $23.81M
|
| Aug 1 |
Ultragenyx: Q2 Earnings Snapshot
|
| Aug 1 |
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
|
| Jul 31 |
Ultragenyx Pharmaceutical Q2 2024 Earnings Preview
|
| Jul 25 |
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
|
| Jul 24 |
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
|
| Jul 22 |
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
| Jul 18 |
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
|
| Jul 17 |
Ultragenyx to begin phase 3 study of Angelman syndrome asset by year end
|
